Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $78.52, while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCSH | VRTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $80.20 | $529.65 |
52-Week Low | $78.41 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $78.61, up 0.17% with neutral technical signals. The ETF offers a short 2.7-year duration and a 4.77% yield, attracting income-focused investors amid stable rate expectations. Recent institutional activity shows mixed positioning, with some firms reducing stakes while others increase holdings. Credit spreads remain tight, limiting near-term upside potential but providing downside protection.
Outlook is cautious due to unattractive entry points and tight spreads. The ETF suits conservative portfolios seeking steady income with low volatility, though limited rate cuts in 2026 may cap gains. Risks include credit spread widening and competition from higher-yielding alternatives.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
